Waters Corporation $WAT Shares Bought by NewEdge Advisors LLC

NewEdge Advisors LLC increased its position in Waters Corporation (NYSE:WAT) by 10,340.0% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 3,654 shares of the medical instruments supplier’s stock after acquiring an additional 3,619 shares during the period. NewEdge Advisors LLC’s holdings in Waters were worth $1,088,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Anchor Investment Management LLC bought a new stake in Waters in the first quarter worth about $27,000. Resources Management Corp CT ADV bought a new position in shares of Waters during the 1st quarter valued at about $27,000. Zions Bancorporation National Association UT boosted its position in shares of Waters by 121.2% during the 4th quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 40 shares in the last quarter. Vision Retirement LLC acquired a new position in shares of Waters in the 1st quarter worth approximately $29,000. Finally, Bollard Group LLC acquired a new position in shares of Waters in the 1st quarter worth approximately $29,000. Institutional investors own 94.01% of the company’s stock.

Wall Street Analysts Forecast Growth

WAT has been the subject of several recent research reports. Royal Bank Of Canada increased their target price on shares of Waters from $435.00 to $475.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. TD Cowen upgraded shares of Waters from a “hold” rating to a “buy” rating and lifted their price target for the stock from $408.00 to $475.00 in a research report on Wednesday, August 5th. Wolfe Research started coverage on Waters in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $425.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on Waters from $330.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, May 6th. Finally, Barclays raised their price objective on Waters from $425.00 to $460.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $420.35.

Insider Activity

In other news, Director Christopher A. Kuebler sold 3,626 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the transaction, the director directly owned 17,808 shares in the company, valued at $7,086,515.52. The trade was a 16.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.31% of the stock is owned by company insiders.

Waters Price Performance

Shares of WAT opened at $407.75 on Tuesday. The company has a market capitalization of $40.06 billion, a price-to-earnings ratio of 101.68, a P/E/G ratio of 2.40 and a beta of 1.19. Waters Corporation has a fifty-two week low of $282.77 and a fifty-two week high of $420.26. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.86 and a quick ratio of 1.29. The business’s 50-day moving average is $378.07 and its 200-day moving average is $346.12.

Waters (NYSE:WAT) last posted its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 EPS for the quarter, topping the consensus estimate of $3.01 by $0.04. Waters had a net margin of 3.58% and a return on equity of 11.27%. The business had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.62 billion. During the same period last year, the company posted $2.95 earnings per share. The firm’s quarterly revenue was up 113.3% compared to the same quarter last year. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Equities research analysts expect that Waters Corporation will post 14.57 EPS for the current fiscal year.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.